Treats serious bacterial infections caused by susceptible strains of the designated…. ANDA 65407, held by Mylan Labs Ltd. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 65407 (Tobramycin Sulfate), held by Mylan Labs Ltd, was first approved by FDA on Mar 11, 2008, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp. Lower respiratory tract infections caused by P. aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains). Serious central-nervous-system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tobramycin SulfateEQ 40MG BASE/ML · injectable;injection | Tobramycin Sulfate | Rx |
| Feb 10, 2023 | Supplement 21Labeling · Standard review | Approved | None posted |
| Jan 18, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 18, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 24, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 23, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 11, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters